Prostate Cancer Diagnostics and Minimally Invasive Treatments Market

Prostate cancer is the second most commonly occurring cancer in men (after lung cancer), and the fourth most commonly occurring cancer overall. Almost 1.5 million new cases of prostate cancer were recorded in 2022 worldwide, and there were an estimated 397,000 deaths from the disease in 2022, making it the eighth-leading cause of cancer deaths worldwide.

The global prostate cancer diagnostic products market is expected to experience healthy growth over the period covered by this analysis (2023–28). The main growth drivers are the increasing incidence of prostate cancer worldwide, an expanding elderly population of men susceptible to prostate cancer, improved early diagnosis guidelines and increasing patient awareness of and demand for minimally invasive and predictive diagnostic tests, including those used to guide therapy. Increasing patient awareness of prostate cancer diagnostic options, improved accessibility, as well as technological advancements in accurately diagnosing more aggressive types of cancer and more precisely targeting cancer cells for biopsy are additional factors that will help support market growth.

If you are not a subscriber to Meddevicetracker and would like to purchase this report, please send an email to [email protected]. If you would like more information about obtaining a subscription to the Meddevicetracker database and report library, please send an email to [email protected].